Accessibility Menu
Oculis Ag logo

Oculis Ag(NASDAQ) OCS

Market Cap$636.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.
Since IPO (2021)+15%
5 YearN/A
1 Year-38%
1 Month-8%
$11.04
-0.81%
-0.09Today
Oculis Ag last closing stock price
MetricPriceDate
Last closeUSD 11.022026-07-27
Oculis Ag stock price return by period
PeriodPrice returnPrice at period startPeriod start date
1 week-6.05%USD 11.732026-07-20
1 month-8.17%USD 12.002026-06-26
3 month-58.76%USD 26.722026-04-28
Year to date-44.82%USD 19.972025-12-31
1 year-37.78%USD 17.712025-07-25
3 year-11.41%USD 12.442023-07-28
Since inception+14.74%USD 9.702021-05-18

Oculis Ag Financials at a Glance

Market Cap

$636.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Revenue (TTM)

CHF 504.00K

Net Income (TTM)

-CHF 95.06M

EPS (TTM)

-$2.14

P/E Ratio

-5.20

Dividend

$0.00

Beta (Volatility)

0.88 (Low)

Price

$11.04

Volume

16,994

Open

$11.51

Previous Close

$11.04

Daily Range

$10.89 - $11.51

52-Week Range

$10.52 - $34.48

Estimated Earnings Date

Aug 6, 2026

OCS News

SellAlert-Blue.png

Nan Fung Group Sells $4.3 Million in Oculis Shares As Lead Drug Stumbles

Andy GouldJun 8, 2026

OCS: Motley Fool Moneyball Superscore

58

Our CEO Is Handing Members His Secret Weapon

It's called Motley Fool Moneyball, our new proprietary AI tool

We spent over half a million dollars in R&D to build a tool that makes stock research faster, sharper, and smarter. Our analysts use it every day, and now, you can too.

Get Access Now

About Oculis Ag

Oculis Holding AG is a biopharmaceutical company focused on developing innovative eye drop medications for various ocular conditions. The company is currently advancing several key products through clinical trials, targeting both anterior and posterior segments of the eye.

Products and Services
  • OCS-01: A topical formulation of dexamethasone for diabetic macular edema
  • OCS-02: A biological candidate for treating dry eye disease in Phase 2b trials
  • OCS-05: A neuroprotective agent targeting acute optic neuritis and other disorders
Growth Outlook
  • Strong pipeline with multiple candidates in advanced clinical stages
  • Potential market expansion as ocular diseases increase globally
  • Strategic partnerships may enhance research and development capabilities
Financial Highlights
  • Recent quarterly net income of -29.5 million CHF, reflecting ongoing R&D investments
  • Cash and short-term investments totaled 221.4 million CHF as of March 31, 2026
  • Current ratio of 5.18 indicates strong liquidity position
Oculis Holding AG is positioned in the biotechnology sector, focusing on unmet medical needs in ophthalmology. The company’s lead product, OCS-01, is in Phase 3 trials, which could significantly impact its market presence upon successful completion. The ongoing development of OCS-02 and OCS-05 further demonstrates the company's commitment to addressing a range of ocular conditions. Financially, Oculis has maintained a robust liquidity position, with substantial cash reserves to support its research and development efforts. Despite recent net losses, the company’s strategic focus on innovative therapies may attract investor interest as it progresses through critical clinical stages. The potential for market expansion and the development of strategic partnerships could further enhance growth prospects in the coming years.
AI Generated • Jul 21, 2026

Industry

Pharmaceuticals

Sector

Health Care

Employees

60

CEO

Riad Sherif, MD, MBA

Website

www.oculis.com

Headquarters

Zug, ZG 6300, CH

OCS Financials

Key Financial Metrics (TTM)

Gross Margin

-2889.37%

Operating Margin

-16740.95%

Net Income Margin

-18861.29%

Return on Equity

-57.09%

Return on Capital

-39.85%

Return on Assets

-39.08%

Earnings Yield

-19.23%

Dividend Yield

0.00%

Payout Ratio

0.00%

Stock Overview

Market Cap

$636.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

Shares Outstanding

57.17M

Volume

16.99K

Avg. Volume

706.51K

Financials (TTM)

Gross Profit

-CHF 14.56M

Operating Income

-CHF 84.37M

EBITDA

-CHF 94.13M

Operating Cash Flow

-CHF 62.88M

Capital Expenditure

-CHF 295.16K

Free Cash Flow

-CHF 63.17M

Cash & ST Invst.

CHF 221.37M

Total Debt

CHF 2.24M

Oculis Ag Performance Analysis

Oculis Ag annual revenue and year-over-year revenue growth by fiscal year
Fiscal yearPeriod endRevenueYoY growth
20222022-12-31CHF 0N/A
20232023-12-31CHF 0N/A
20242024-12-31CHF 0N/A
20252025-12-31CHF 0N/A
Oculis Ag sequential (quarter-over-quarter) revenue growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-30N/A
Q32025-09-30-6.9%
Q42025-12-31-100.0%
Q12026-03-31N/A
Oculis Ag annual diluted earnings per share and year-over-year EPS growth by fiscal year
Fiscal yearPeriod endDiluted EPSYoY growth
20222022-12-31CHF -1.12N/A
20232023-12-31CHF -3.31195.5%
20242024-12-31CHF -2.41-27.1%
20252025-12-31CHF -2.28-5.4%
Oculis Ag sequential (quarter-over-quarter) diluted earnings per share growth by fiscal quarter
Fiscal quarterPeriod endQoQ growth
Q22025-06-3029.0%
Q32025-09-3034.7%
Q42025-12-31-31.2%
Q12026-03-31-19.0%

Revenue Growth Rate

Annual and quarterly growth comparison

Currently no data to display.

Earnings Per Share Growth Rate

Annual and quarterly EPS growth comparison

Quarterly Performance

Name
Q1 2026YOY CHG

Revenue

CHF 0.00

N/A

Gross Profit

-CHF 157.43K

N/A

Gross Margin

0.00%

N/A

Market Cap

$636.30MMarket cap calculated using publicly traded shares outstanding only. Does not include unlisted, private, or dual-class non-traded shares. Implied market cap may vary.

N/A

Market Cap/Employee

$10.60M

N/A

Employees

60

N/A

Net Income

-CHF 29.50M

+11.2%

EBITDA

-CHF 29.26M

+10.9%

Quarterly Fundamentals

Name
Q1 2026YOY CHG

Total Cash

CHF 221.37M

+21.7%

Total Debt

CHF 2.24M

+103.2%

Accounts Receivable

CHF 1.57M

-38.7%

Inventory

CHF 0.00

N/A

Long Term Debt

CHF 1.83M

+128.6%

Short Term Debt

CHF 414.76K

+36.4%

Return on Assets

-39.08%

N/A

Return on Invested Capital

-42.29%

N/A

Free Cash Flow

-CHF 15.54M

+22.5%

Operating Cash Flow

-CHF 15.54M

+18.1%

Other Investments to Explore

People Also Watch

Symbol / CompanyPricePrice Chg
BBOTBridgeBio Oncology Therapeutics Inc.
$8.75-0.79%
SANASana Biotechnology, Inc.
$3.28+3.14%
PHATPhathom Pharmaceuticals, Inc.
$11.95+4.46%
NKTRNektar Therapeutics
$71.35+0.88%

Trending Stocks

Symbol / CompanyPricePrice Chg
INTCIntel
$91.67-0.01%
NVDGraniteShares ETF Trust - GraniteShares 2x ShortDA Daily ETF
$5.25+0.10%
AALAmerican Airlines Group
$14.95+0.03%
TSLLDirexion Shares ETF Trust - Direxion Daily Tsla Bull 2x Shares
$7.24-0.02%

Questions About OCS

What is the current price of Oculis Ag?

Oculis Ag is trading at $11.04 per share.

What is the 52-week range for Oculis Ag?

Over the past 52 weeks, Oculis Ag has traded between $10.52 and $34.48.

How much debt does Oculis Ag have?

As of the most recent reporting period, Oculis Ag reported total debt of CHF 2.80M.

How much cash does Oculis Ag have on hand?

Oculis Ag reported CHF 80.35M in cash and cash equivalents in its most recent financial results.

What is Oculis Ag’s dividend yield?

Oculis Ag does not currently have a dividend yield.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.

View Premium Services